NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • Impact
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • Ethics in the NIHR Oxford BRC
        • Medical Statistics
        • Infections in Oxfordshire Database (IORD)
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient and Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Pre-Doctoral Research Fellowships
    • Senior Research Fellowships
    • Doctoral Awards
    • Post-Doctoral Awards
    • Pre-Application Programme
    • Other Funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
    • Success Stories
  • Industry and Partnerships
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Partnerships News
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

Patient and Public Involvement

Home > Welcome > PPIE Case Studies > FLU008 study, Jenner Institute Oxford

PPIE Case Studies

PPIE CASE STUDY CATEGORIES

Cancer | Cardiovascular Medicine | Diabetes and Metabolism | Digital Health from Hospital to Home | Genomic Medicine | Haematology and Stem Cells | Imaging | Life-saving Vaccines | Metabolic Experimental Medicine | Musculoskeletal | Obesity, Diet and Lifestyle | Respiratory Medicine | Stroke and Vascular Dementia | ALL

FLU008 study, Jenner Institute Oxford

Listed under Life-saving Vaccines

Background

The FLU008 study was a phase I, open label study to determine the safety and immunogenicity of candidate influenza vaccine MVA-NP+M1, manufactured on the AGE1.CR.pIX novel avian cell line. Earlier trials had already shown this vaccine to be safe and effective in producing an immune response, but the way it was produced previously meant that it was difficult to make large enough amounts.

The vaccine used in the FLU008 study was developed using a new, more efficient process aiming to show that this new process did not change the safety or effectiveness of the vaccine. We enrolled a total of 6 healthy adult volunteers aged 18 to 50. The vaccine was administered by intramuscular injection (into the muscle of their upper arm) on the day of vaccination and volunteers were followed up for 4 weeks.

What we did

At the time of publication of the FLU008 study and as part of our commitment to research participants, we sent a plain-language summary of the findings to those who took part in the FLU008 study. We wanted to make sure that we presented the research results to our participants in a format understandable to laypersons, therefore we took the initiative to involve the general public in the development and review of the summary prior to sending it to the study participants.

We advertised this PPI opportunity to the general public through the Patients Active in Research (PAIR) platform, which is run by the NIHR Oxford Biomedical Research Centre. Within a few days, we received a response from 6 people interested in contributing to this PPI activity. The initial draft of the study summary was sent to them via email for feedback and any further correspondence with the PPI contributors was also via email.

What difference did it make?

We received very valuable feedback from the PPI contributors. We incorporated most of the suggested changes, which overall related to the wording and terminology used and the layout of the summary document. By involving the general public in the writing of the study summary, we are ensuring that the information sent to research participants is clear, understandable and jargon-free.

For Patients and the Public

  • Welcome
  • Opportunities for patients and the public
  • Training for patients and the public
  • Public events
Register for the involvement email bulletin
Follow @OxfordPPI
RESEARCHER GUIDANCE →

More Information

  • Patient and public groups
    • Patient and Public Advisory Group
    • Diversity in Research Group
  • Meet the team
  • Case Studies
  • Strategy
  • Videos
  • News

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

Oxford BRC on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2026 NIHR Oxford Biomedical Research Centre